Quotient Sciences Significantly Expands Formulation and Manufacturing Operations in U.K.
Quotient Sciences, a leading drug development services organization, has significantly expanded its formulation development and clinical trial manufacturing operations at its Reading, U.K., facility. The program’s investment has tripled the site’s GMP capacity, added new equipment for solid oral dose manufacturing and significantly increased staffing levels.
“Our investment in Reading is in direct response to increasing client demand,” said Mark Egerton, CEO of Quotient Sciences. “With drug development expertise on both sides of the Atlantic, we are optimally positioned to serve our global client base. The Reading site can support customers with stand-alone formulation and clinical trial manufacturing services that can also be integrated into Translational Pharmaceutics® programs.”
Activities at the 48,000-square-foot Reading facility are focused on small molecule drug products for oral and inhaled delivery spanning drug substance characterization, formulation development and clinical trial manufacturing. The site routinely handles poorly soluble compounds and is equipped with a broad range of technologies including spray drying, hot melt extrusion, lipidic systems and micronization.
Its capacity is bolstered by 13 GMP manufacturing suites to support traditional Phase I-III clinical trial manufacturing and Translational Pharmaceutics programs that integrate real-time adaptive manufacturing and clinical research. This flexible and nimble approach allows batch sizes to be tailored to the precise needs of a clinical trial. Drug products are rapidly supplied into global patient trials and clinical pharmacology units, delivering substantial benefits to customers including flexible dose adjustments, reductions in manufacturing costs and shorter manufacturing lead times.
Quotient has more than 800 employees across six operating sites in the U.K. and U.S., serving a global customer base of more than 150 biotech and pharma clients.
About Quotient Sciences
Quotient Sciences, a global pharmaceutical development, clinical pharmacology and clinical and commercial manufacturing organization, delivers innovative, customized solutions for pharmaceutical and biotech customers through both individual and integrated services. Its Translational Pharmaceutics® platform integrates formulation development, real-time adaptive GMP manufacturing and clinical research for the continuous improvement of drug development programs, and is proven to accelerate timelines and reduce cost. Visit quotientsciences.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181105005087/en/
Contact information
SCORR Marketing
Jane Byram, +1-512-626-2758
jane@scorrmarketing.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Lantern Appoints Jeff Williams as Chief Product Officer, Marking Expansion into the US2.9.2025 21:03:00 EEST | Press release
Lantern, the data intelligence platform for private markets, today announced the appointment of Jeff Williams as its first Chief Product Officer (CPO). Based in the United States, Jeff’s appointment marks a major milestone as Lantern establishes its presence in North America, to support its rapidly growing global client base. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250902271705/en/ Jeff Williams, Lantern Chief Product Officer Jeff brings more over 15 years’ experience at the intersection of private markets and technology. Most recently, he served as Chief Strategy Officer at Altvia, where he played a central role in shaping product strategy, guiding product launches, and driving growth. Edward Moore, Founder and CEO of Lantern, commented: “Jeff has a rare blend of product expertise and deep knowledge of private markets. He’s led product strategy through periods of intense growth and complexity, and his experience will
Coherent Solutions secures strategic investment from IceLake Capital to fuel global growth2.9.2025 19:48:00 EEST | Press release
Coherent Solutions, a global digital solutions engineering firm, has secured a strategic investment from IceLake, a leading private equity investor specializing in partnering with high-growth business services organizations. The partnership will accelerate Coherent Solutions’ global expansion and solution offerings, advancing its mission to deliver measurable digital value creation for clients worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250902336956/en/ Coherent Solutions has secured a strategic investment from IceLake, advancing its mission to deliver measurable digital value creation for clients worldwide. This year marks Coherent Solutions’ 30th anniversary. Since its founding in 1995, the company has partnered with some of the world’s largest brands and most ambitious growth companies to design, develop, and launch sophisticated digital platforms and solutions. “The partnership with IceLake is a strong vote
Proteintech Launches “Able” AI – A First-of-Its-Kind Tool to Accelerate Scientific Discovery2.9.2025 18:18:00 EEST | Press release
Proteintech, a global leader in antibodies and life science solutions, today announced the launch of Able AI, a first-of-its-kind artificial intelligence tool that is now available on ptglab.com. Finding the most suitable antibodies from the vast pool of potential products is a challenge. Able helps scientists pinpoint the right antibody based on their research needs, while also providing all relevant information and associated scientific knowledge. In addition, it offers detailed guidance on product specific experimental procedures, significantly reducing the time spent on planning and product selection. This release follows Proteintech’s successful introduction of 3D Epitope Mapping earlier this year, which advanced researchers’ ability to visualize antibody binding sites through experimental and AI-powered modelling. This capability reduces guesswork and trial-and-error, enabling scientists to better design experiments and develop products with greater precision. “Able represents th
MSP Sports Capital Confirms Sale of its Holdings in McLaren Racing to McLaren Group Limited2.9.2025 18:02:00 EEST | Press release
As announced earlier today, McLaren Group Limited has completed the purchase of MSP Sports Capital’s equity interest in McLaren Racing, including its Formula 1 Team. The transaction will enable Bahrain Mumtalakat Holding Company and CYVN Holding, an advanced mobility operator and investment vehicle based in Abu Dhabi, to increase their share and assume full ownership of the iconic British motor racing business. Mumtalakat will continue as majority shareholder with CYVN Holdings owning a non-controlling stake. MSP’s investment came at a pivotal moment in the business, providing vital capital that contributed to the company’s efforts in stabilizing business operations during the COVID-19 pandemic, funding infrastructure upgrades, and retaining and recruiting world-class talent. Over the last five years, with the support received from its shareholders, McLaren has returned to the front of the Formula 1 grid, rebuilt its competitiveness across multiple racing series, and enhanced its long
Textron Aviation Expands ProAdvantage Portfolio With Launch of ProParts+ for Cessna Citation 525 Series2.9.2025 18:00:00 EEST | Press release
Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company, today announced the launch of ProParts+, a new addition to the company’s industry-leading ProAdvantage support programs, designed specifically for Cessna Citation 525 series operators. ProParts+ builds on the trusted foundation of the ProParts program, offering expanded coverage to address key customer identified priorities and enhance operational predictability. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250902524070/en/ Textron Aviation announced the launch of ProParts+, a new addition to the company’s industry-leading ProAdvantage support programs, designed specifically for Cessna Citation 525 series operators. (Textron Aviation) “Expanding our ProAdvantage portfolio with ProParts+ reflects our continued investment in the long-term support of the Citation 525 Series,” said Brad White, senior vice president, Global Parts Distribution. “ProParts+ is a direct res
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom